Finerenone Beats Spironolactone: New Study on Diabetic Kidney Disease Protection

Описание: Finerenone spironolactone comparison diabetic kidney disease chronic kidney disease type 2 diabetes heart kidney protection real-world study
Discover the latest breakthrough in treating chronic kidney disease (CKD) and type 2 diabetes (T2D) with finerenone outperforming spironolactone. This major international analysis from Nature Communications reveals finerenone reduces all-cause mortality by 69%, lowers major kidney deterioration by 53%, and cuts cardiovascular events by 26%. Learn how finerenone offers better safety with less hyperkalaemia risk.
Led by experts from National Taiwan University Hospital, the study emulates a randomized trial using data from over 2,200 patients across 21 countries. Explore the selective mechanism of mineralocorticoid receptor antagonists and their impact on inflammation, fibrosis, and electrolyte balance.
Why switch to finerenone for high-risk patients? Get insights into real-world evidence that could shape clinical guidelines. Watch for more on kidney health, diabetes management, and cardiovascular protection.